CHOP is a combination chemotherapy regimen made up of four drugs, each represented by a letter in the name. It is one of the most widely used treatments for non-Hodgkin lymphoma, particularly an aggressive type called diffuse large B-cell lymphoma (DLBCL). Most people today receive it alongside a targeted drug called rituximab, making the full regimen R-CHOP.
What the Letters Stand For
Each letter in CHOP refers to a specific drug:
- C: Cyclophosphamide, a chemotherapy drug that stops fast-growing cancer cells from dividing and producing new cells.
- H: Doxorubicin (sometimes called hydroxydaunomycin), a chemotherapy drug that damages cancer cell DNA and prevents damaged cells from continuing to grow.
- O: Vincristine (brand name Oncovin), a plant-derived chemotherapy drug that also blocks cancer cell division.
- P: Prednisone, a steroid that helps kill cancer cells and reduces inflammation that can interfere with treatment.
Three of these drugs attack cancer cells through slightly different mechanisms, which is the core strategy: by hitting the cancer from multiple angles simultaneously, the combination is more effective than any single drug alone. Prednisone plays a supporting role, enhancing the other drugs’ activity and helping manage side effects like swelling and allergic reactions.
What CHOP Treats
CHOP is primarily used for non-Hodgkin lymphoma, a group of blood cancers that start in white blood cells called lymphocytes. Its most common target is diffuse large B-cell lymphoma (DLBCL), the single most common type of lymphoma, accounting for about 25% of all lymphoproliferative disorders. DLBCL is aggressive, meaning it grows quickly, but that fast growth also makes it more vulnerable to chemotherapy.
The regimen can also be used for other types of non-Hodgkin lymphoma, including peripheral T-cell lymphomas and certain cases of follicular lymphoma when more aggressive treatment is needed.
Why Rituximab Is Usually Added
Most patients with B-cell lymphomas now receive R-CHOP rather than plain CHOP. The “R” stands for rituximab, a targeted therapy that locks onto a protein called CD20 found on the surface of cancerous B-cells. Rituximab is given intravenously on the first day of each cycle, alongside the other drugs.
Adding rituximab was a major advance. In a landmark trial published in the New England Journal of Medicine, patients who received R-CHOP had a complete response rate of 76%, compared to 63% for those who received CHOP alone. Event-free survival and overall survival were both significantly longer in the R-CHOP group, with no meaningful increase in side effects. This finding transformed R-CHOP into the standard first-line treatment for CD20-positive DLBCL, and it has remained the backbone of care for over two decades.
How Treatment Is Structured
CHOP is given in cycles, with each cycle lasting 21 days (three weeks). A typical course involves six to eight cycles, meaning the entire treatment spans roughly four to six months. On the first day of each cycle, cyclophosphamide, doxorubicin, and vincristine are delivered intravenously at a clinic or infusion center. Prednisone is taken by mouth, usually for the first five days of each cycle.
The three-week gap between cycles exists to give your body time to recover, particularly your bone marrow, which takes a hit from chemotherapy. White blood cell counts typically drop to their lowest point about 7 to 14 days after each infusion, then climb back up before the next cycle begins. Your oncology team will run blood tests before each cycle to confirm your counts have recovered enough to proceed safely.
Common Side Effects
Because CHOP targets fast-dividing cells, it affects healthy fast-dividing cells too, particularly hair follicles, the lining of the digestive tract, and bone marrow. Hair loss is nearly universal and typically begins within the first few weeks. Hair regrows after treatment ends, though it sometimes comes back a different texture or color initially.
Nausea and vomiting are common but are usually well controlled with anti-nausea medications given before and after each infusion. Fatigue tends to build over the course of treatment, often peaking a few days after each cycle and gradually improving before the next one. Many people describe a predictable rhythm: feeling worst during the first week after infusion, then steadily better during weeks two and three.
Low white blood cell counts (neutropenia) increase your risk of infection, especially in the second week of each cycle. Fever during this window is taken seriously and typically requires prompt medical evaluation. Mouth sores, changes in appetite, and diarrhea or constipation can also occur.
Nerve and Heart Risks
Vincristine can cause peripheral neuropathy, a tingling, numbness, or pain in the fingers and toes. This tends to be cumulative, meaning it can worsen with each cycle. For some people, mild neuropathy lingers for months after treatment ends, though it usually improves gradually.
Doxorubicin carries a specific risk to the heart. The FDA notes that cumulative doses above 450 to 550 mg per square meter of body surface area are associated with a sharply increased risk of irreversible heart failure. Standard CHOP dosing stays well below this threshold, but your oncologist will monitor your heart function before and during treatment, typically with an echocardiogram or similar scan. This lifetime dose limit also means that if you ever need doxorubicin again for a different cancer, previous exposure counts toward the cap.
How Effective Is R-CHOP?
For DLBCL, R-CHOP cures a substantial proportion of patients. Five-year overall survival rates across major clinical trials range from about 62% to as high as 98%, depending on the stage and risk profile of the disease. A commonly cited range for the broader DLBCL population is 60% to 95%, with younger patients and those with limited-stage disease faring best. In one large trial (GOYA) involving 710 patients, the five-year overall survival rate with R-CHOP was about 78%.
The word “cure” is used carefully in oncology, but DLBCL is one of the cancers where it genuinely applies. Roughly 50% to 70% of patients treated with R-CHOP achieve long-term remission and never relapse. For those whose lymphoma does return or doesn’t respond to R-CHOP initially, second-line treatments including newer targeted therapies and, in some cases, CAR-T cell therapy are available.
Newer Alternatives on the Horizon
R-CHOP has been the standard for DLBCL since the early 2000s, and while many newer regimens have tried to beat it, most have not succeeded in head-to-head trials. One recent exception is pola-R-CHP, which swaps vincristine for a targeted drug and has shown modestly improved outcomes in certain analyses, with predicted five-year overall survival rates of about 77% compared to 71% for R-CHOP.
The treatment landscape for B-cell lymphomas is evolving, with newer classes of drugs including bispecific antibodies and antibody-drug conjugates showing promise, particularly for patients whose disease relapses after R-CHOP. For now, R-CHOP remains the first-line standard for most patients with DLBCL, and the NCCN guidelines continue to include it as a cornerstone of treatment.